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Treatment algorithms and clinical practice guidelines are
often implemented within healthcare institutions as
measures to reduce healthcare costs while improving
patient outcomes. As antibiotic resistance rates continue to
rise and therapeutic options remain limited, urinary tract
infections (UTIs) represent a growing public health concern.
Based on the institutional formulary, clinical experience,
local resistance patterns, and consensus guidelines, the
P&T Committee at Baptist Health South Florida agreed
upon an evidence-based treatment pathway for UTIs to be
used as guidance for empiric antibiotic treatment. The goal
of this study was to assess whether this pathway is an
effective antibiotic stewardship effort to promote
appropriate antibiotic use.
All authors of this presentation have nothing to disclose
concerning possible financial or personal relationships with
commercial entities that may have direct or indirect
interest in the subject matter of this presentation.
 Bi-phasic, IRB approved study conducted on adult
patients admitted to Baptist Hospital of Miami
 Phase I was a retrospective chart review of 50 randomly
selected patients admitted with a UTI between
November 2016 and October 2017
 Phase II was a prospective review of 50 patients with a
positive urine culture between January 2018 and March




• Acute bacterial prostatitis
• Coexisting infections
 Primary outcome: Percent of patients who received
optimal empiric antibiotic treatment and duration of
therapy before and after implementation of the pathway
 Secondary outcome: length of stay before and after
pathway
 Appropriateness of antibiotic therapy was defined by
the P&T approved treatment algorithm
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Conclusion
Purpose
To evaluate appropriateness of antibiotic selection and
duration of treatment for urinary tract infections (UTIs)
before and after implementation of a treatment pathway
within Baptist Hospital of Miami.
Results
Implementation of a UTI treatment pathway improved
appropriate empiric antimicrobial use, reduced average
length of stay, and reduced average duration of
antimicrobial therapy, thus favoring patient outcomes and
healthcare costs.
• There were no significant differences in baseline
characteristic between the two groups
• The majority of patients were female and had a
diagnosis of severe and/or complicated UTI
• For the primary outcome of optimal antibiotic selection
and duration of therapy, 15 (30%) of the patients in
phase I prior to pathway implementation were treated
appropriately according to the algorithm, while 29 (58%)
of patients were treated appropriately in phase II after
pathway implementation (p=0.05)
• For the secondary outcome, average length of stay was
reduced from 7.8 days in phase I to 6.7 days in phase II,
although this difference was not found to be statistically
significant (p=0.66)
• Average duration of therapy was reduced from 8 days























Asymptomatic bacteriuria, n (%)
Acute uncomplicated cystitis, n (%)
Uncomplicated pyelonephritis, n (%)




















Optimal antibiotic & duration, n (%)
Optimal empiric antibiotic, n (%)











Average length of stay, days 7.8 6.4 0.66
Overall Outcomes
Average duration of therapy, days
Total days of antibiotic therapy















Asymptomatic bacteriuria, n (%) 0/2 (0%) 1/2 (50%) 0.32
Uncomplicated cystitis, n (%) 9/12 (75%) 13/13 (100%) 0.06
Uncomplicated pyelonephritis, n (%) 12/14 (86%) 12/12 (100%) 0.19
Severe and/or complicated UTI, n (%) 6/22 (27%) 12/23 (52%) 0.09
